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282 The Journal of Thoracic and CardioObjective: The purpose of this study was to evaluate the outcome and risk factors for
implant failure in pediatric patients who underwent pulmonary position homograft
placement for right ventricular outflow tract obstruction compared with conduit
placement as a component of the Ross operation. Actuarial 5-year survivals for
cryopreserved right ventricle–to–pulmonary artery homografts range from 55% to
94% at all ages. It is not known whether there is a difference in homograft durability
when utilized for right ventricular outflow tract obstruction or as part of the Ross
operation.
Methods: The records of all pediatric patients receiving a right ventricle–to–
pulmonary artery homograft from July 1989 through October 2003 were reviewed.
Ninety-eight consecutive patients were studied (26 Ross, 72 non-Ross). In addition
to Ross versus non-Ross comparisons, other potential risk factors for homograft
failure analyzed included age at operation, follow-up time, type of surgery, and
homograft type and size.
Results: Ross and non-Ross patients were comparable in age at the time of the
operation and follow-up time. Homograft failure rates were 12% and 51% for Ross
and non-Ross patients, respectively. Freedom from reintervention was 93% in the
Ross and 66% in the non-Ross group at 5 years (P .019). On multivariate analysis,
non-Ross operation and age less than 2 years were significant predictors of
homograft failure.
Conclusions: 1. Pediatric patients undergoing the Ross operation have longer
homograft survival than pediatric patients treated for right ventricular outflow tract
obstruction, independent of age. 2. Homografts placed in patients less than 2 years
of age have shorter homograft survival.
In 1966, Ross and Somerville1 reported the first use of an aortic homograft toestablish right ventricle–to–pulmonary artery continuity in a patient with tetral-ogy of Fallot and pulmonary atresia. Since that time, pulmonary position
homografts have been used in a variety of right-sided congenital heart lesions.
Actuarial 5-year homograft survivals for cryopreserved homografts are reported to
range between 55% and 94%,2-23 with the shortest durability noted in patients less
than 2 years of age.4
Pulmonary position homografts also are used to replace pulmonary autografts
explanted to repair left-sided outflow disease (the Ross operation). Several factors
may be likely to favor increased pulmonary conduit durability in Ross patients
compared with those with right ventricular outflow tract obstruction, including later
age at operation (allowing for larger homografts), more normal pulmonary artery
architecture, absence of severe right ventricular hypertrophy, and more natural
positioning of the homograft. However, this concept has not been systematically
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Dstudied. Only a small number of Ross and non-Ross patients
have been compared, and these were in the context of a
broad study of cryopreserved homografts in the pulmonary
position.5 The present study directly compares Ross versus
non-Ross homograft survival in pediatric patients followed
serially after surgical intervention during the first decade of
life.
Methods
The hospital records of all patients less than 10 years of age
receiving primary cryopreserved right ventricle–to–pulmonary ar-
tery homografts at Children’s Hospital of New York from July
1989 through October 2003 were reviewed. Cryopreserved ho-
mografts were obtained from Cryolife, Inc (Kennesaw, Ga). All
patients who were followed up for longer than 4 months were
included in the study unless graft failure occurred earlier (n  5).
Hospital records, including operative reports, catheterization data,
and echocardiographic studies, were retrospectively reviewed. The
study protocol was reviewed and approved by the institutional
review board. Ninety-eight consecutive patients were included in
the study.
Homograft failure was defined as need for surgical replacement
or catheter balloon dilatation and/or stent implantation because of
right ventricular outflow tract obstruction. Indications for interven-
tion were determined by the primary cardiologist on the basis of
the presence of right ventricular hypertrophy and 2-dimensional
and Doppler echocardiographic evidence of significant outflow
tract obstruction. In addition to Ross versus non-Ross compari-
sons, age at operation, length of follow-up, type of operation,
homograft type, and size were analyzed as other potential risk
factors for homograft failure.
Statistical analysis was performed with the SAS 8.2 software
(SAS Institute). Continuous variables were compared between
subjects with and without graft failure by using unpaired t test.
Categorical variables were compared by the Fisher’s exact test.
Kaplan-Meier curves were constructed for graft survival, and the
effect of Ross versus non-Ross operation, as well as other potential
covariates, was assessed by Cox proportional hazards models.
Variable selection was performed by backwards elimination for
multivariate modeling. Values are presented as means  SD.
Results
Ninety-eight patients were included in the study (Table 1).
TABLE 1. Patient characteristics
Ross
(n  26)
Non-Ross
(n  72)
TOF
(n 
Age at operation (y) 3.4 3.4 2.1 0.3 2.3
Homograft size (mm) 19.2 3.9 16.5 4.8 16.5
Pulmonary type homograft 19 (73%) 29 (40%) 16 (43
Follow-up time (y) 5.2 4.0 4.8 3.8 5.5
Values are presented as means  SD where shown. TOF, Tetralogy of FaTwenty-six patients underwent the Ross procedure for
The Journal of Thoracileft-sided heart disease. Seventy-two patients with right
ventricular outflow tract obstruction (non-Ross group)
were studied.
The mean follow-up time was 5.1 years (range, 1.25
months-14.7 years) for all patients (Table 1). The 2 groups
were comparable in age at the time of the operation (3.4 
3.4 vs 2.1  0.3 years, P  .2) and follow-up time (5.2 
4 vs 4.8  3.8 years, P  .7; Table 1). Figure 1 demon-
strates the age distribution, which was not statistically dif-
ferent between the Ross and non-Ross groups. The ho-
mograft size was greater in the Ross group (19.2  3.9 vs
16.5  4.8 mm, P  .02), and more pulmonary type
homografts were used in the Ross group (73% vs 40%, P 
.01; Table 1).
The non-Ross group consisted of 3 major groups (Table
1): patients undergoing homograft placement as a compo-
nent of the Rastelli procedure (n 23), variants of tetralogy
of Fallot (n  37), or truncus arteriosus (n  11) repair.
Patients with truncus arteriosus were the youngest in this
group (0.09  0.3 years), and these patients had smaller
homografts placed (13.0  5.5 mm).
The characteristics of patients with homograft failure are
listed in Table 2. The overall homograft failure rate was
41%. Three (12%) patients in the Ross group had failure of
P value* Total
(n  98)
Rastelli
(n  23)
Truncus
(n  11)
PS
(n  1)
2.7 2.4 0.09 0.3 3.1 .2 2.3  2.7
18.1 4.3 13.0 5.5 18 .02 17.3  4.7
9 (39%) 3 (27%) 1 .01 48 (49%)
4.8 4.4 5  3.6 4.7 .7 5.1  3.9
ariant; PS, pulmonary stenosis. *Ross versus non-Ross.37)
2.5
4.6
%)
4.0Figure 1. Age distribution of the patients.
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Dthe homograft, whereas 37 (51%) in the non-Ross group had
failure of the homograft. Patients in the Ross group expe-
rienced failure at a mean of 83.0  38 months after the
operation, whereas those in the non-Ross group experienced
failure at a mean of 53.2  47 months after the operation
(Table 2). At the time of homograft failure, the maximum
instantaneous homograft gradient, as determined by Dopp-
ler echocardiography, was 90.7  10 mm Hg in the Ross
group and 67.9  29 mm Hg in the non-Ross group (P 
.2). Intervention was required in 8 (8%, all in the non-Ross
group) patients within 6 months, in 18 (18%, all in the
non-Ross group) patients within 3 years, and in 40 (41%, 37
in the non-Ross group and 3 in the Ross group) patients
within 6 years. There was no significant difference in rein-
tervention rates among the different non-Ross procedures.
Homograft survival at 5 years was 93% in the Ross
group (median follow-up time, 52.9 months) and 66% in the
non-Ross group (median follow-up time, 61.3 months), as
shown in the actuarial graph (P  .019, Figure 2).
On univariate analysis, non-Ross operation, age less than
2 years at the time of the operation, smaller homograft size,
and an aortic-type homograft were significant risk factors
for homograft failure; on multivariate analysis, non-Ross
Figure 2. Freedom from homograft intervention stratified accord-
TABLE 2. Homograft failure
Ross
(n  3)
Non-Ross
(n  37)
Homograft failure (%) 12% 51%
Age at operation (y) 4.1 4.8 2.0  2.3
Homograft size (mm) 20.3 4.6 15.6 5.4
Pulmonary type homograft 3 (100%) 15 (41 %)
Failure time from operation (mo) 83.0 38 53.2 47
Values are presented as means  SD where shown. TOF, Tetralogy of Faing to type of operation (P  .019).
284 The Journal of Thoracic and Cardiovascular Surgery ● Auguoperation and age less than 2 years independently re-
mained significant to predict homograft failure (Table 3).
There were 9 infants in the Ross group (4.1  3.9
months; median age, 4 months), of whom only 1 (11%)
patient experienced homograft failure during the follow-up
period (8 months old at the time of the operation, homograft
failure 121 months after the operation). Of 27 infants in the
non-Ross group (2.6  3.7 months; median age, 1 month),
15 (55%) experienced homograft failure within an average
of 56.7  44 months after the operation.
Discussion
Over the past 15 years, the Ross operation has become the
operation of choice for children and young adults with
left-sided outflow tract disease. The increased popularity of
this procedure is largely due to the efficacy of the Ross
operation in relieving left ventricular outflow tract obstruc-
tion in children, the pulmonary autograft’s potential for
growth, and greater experience with the technical demands
of the operation. In addition, the relatively low risk for later
right ventricle–to–pulmonary artery conduit replacement
has generated less concern over the placing of a second
valve at risk (by replacement of the normal native pulmo-
nary artery with a valved conduit) and has contributed to the
preference for this procedure. The latter factor appears to
stem from a general sense that pulmonary circulation con-
duits fare better in Ross patients than in others.
Although the idea that Ross patients have greater right
ventricular conduit durability has been anecdotally noted in
several reports,2,6,7 it has never been formally documented.
The most likely reason for this is that conduit outcome
reviews have predominantly studied older patients in the
Ross group and younger ones in the non-Ross group. Since
conduits generally last longer in older patients, irrespective
of diagnosis or surgical procedure,5 there is a bias favoring
Ross patients on initial univariate analysis. This is usually
confirmed on multivariate analysis, in which the Ross pro-
cedure variable is lost, whereas age at operation and conduit
size remain significant predictors. For example, Niwaya and
Total
(n  40)
TOF
 20)
Rastelli
(n  9)
Truncus
(n  7)
PS
(n  1)
54% 39% 64% 1/1 41%
.1 2.6 1.9 1.8 0.14  0.4 3.1 2.2  2.5
6 5.5 17.3 5.2 12.0  4.8 18 16.0  5.5
(45%) 2 (22%) 3 (43%) 1/1 18 (45%)
.4 50 57.1 50 50.0 46 56 55.4  47
ariant; PS, pulmonary stenosis.(n
2
1
9
52colleagues2 reviewed the results of 331 (259 Ross and 72
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Dnon-Ross) patients who underwent right ventricle–to–pul-
monary artery conduit placement for various indications
(median age, 14 years; 38 patients were less than 3 years
old) and reported that young age and non-Ross operation
were risk factors for failure. However, on multivariate anal-
ysis, the use of an aortic homograft, younger age, and later
year of operation were the only risk factors for homograft
dysfunction. With reasoning similar to that discussed above,
Forbess and coworkers5 used age of the patient to stratify
the implant population into younger and older patient
groups. However, a final comparison of the groups was not
possible because of insufficient patient numbers, with only
9 patients in the Ross group being less than 10 years of age.
The present study was specifically designed to analyze
right ventricular conduit outcomes in Ross and non-Ross
group patients of comparable age and conduit size. In order
to best assess for differences in conduit durability, we
focused on the patient population known to be most sus-
ceptible to conduit failure, those less than 10 years of age.
On multivariate analysis, the non-Ross procedure and age
less than 2 years were shown to be significant independent
predictors of worse outcome.
A common explanation offered for the superior conduit
durability in Ross patients has emphasized the placement of
the homograft in the orthotopic pulmonary position in the
right ventricular outflow tract. One might also speculate that
sternal compression of the more anteriorly placed conduits
could play a role in the earlier failure of non-Ross conduits.
A study by Carr-White and colleagues24 in 2001 suggested
that the predominant mechanism of homograft stenosis was
a poorly understood inflammatory reaction. This suggestion
was based on their noting of early onset of stenosis, rapid
clinical progression, as well as magnetic resonance images
and histology of explanted homografts. The cause of the
inflammation was unclear; however, early postoperative
stretching and lengthening of the homograft causing release
of tissue factors was one possibility suggested. It is possible
to speculate that the extent of that phenomenon might relate
to the degree of peripheral vascular distortion present. To
further tease out that possibility, one would need to analyze
in detail the degree of architectural abnormality in the group
of patients with right-sided outflow tract disease and search
TABLE 3. Risk factors for homograft failure
Univariate analys
Hazard ratio (95% CI)
Non-Ross 4.08 (1.26-13.24)
Age 2 y 2.26 (1.18-4.35)
Aortic homograft 2.30 (1.15-4.60)
Smaller homograft size 2.72 (1.44-5.16)
CI, Confidence interval.for an association with conduit failure. The current retrospec-
The Journal of Thoracitive nature of this study and limited patient number prevented
that analysis from being attempted here. Such information
might be useful, for example, in deciding to forego conduit
placement in patients considered at risk for early conduit
failure and instead consider more technically challenging ap-
proaches to achieving direct right ventricle–to–pulmonary ar-
tery continuity.
We thank Dr Robert Sciacca for the statistical analysis of this
project.
References
1. Ross DN, Somerville JC. Correction of pulmonary atresia with a
homograft aortic valve. Lancet. 1966;2:1446-7.
2. Niwaya K, Knott-Craig CJ, Lane MM, Chandrasekaren K, Elkins RC.
Cryopreserved homograft valves in the pulmonary position: risk anal-
ysis for intermediate-term failure. J Thorac Cardiovascular Surg.
1999;117:141-7.
3. Kirklin JW, Blackstone EH, Maehara T, Pacifico AD, Kirklin JK,
Pollock S, Stewart RW. Intermediate-term fate of cryopreserved allo-
graft and xenograft valved conduits. Ann Thorac Surg. 1987;44:598-
606.
4. LeBlanc JG, Russell JL, Sett SS, Potts JE. Intermediate follow-up of
right ventricular outflow tract reconstruction with allograft conduits.
Ann Thorac Surg. 1998;66(suppl 1):S174-8.
5. Forbess JM, Shah SS, St Louis JD, Jaggers JJ, Ungerleider RM.
Cryopreserved homografts in the pulmonary position: determinants of
durability. Ann Thorac Surg. 2001;71:54-60.
6. Oury JH, Hiro SP, Maxwell JM, Lamberti JL, Duran CMG. The Ross
procedure: current registry results. Ann Thorac Surg. 1998;66(suppl):
S162-5.
7. Elkins RC. The Ross operation: applications to children. Semin Thorac
Cardiovasc Surg. 1996;8:345-9.
8. Chan WC, Fyfe DA, McKay CA, Sade RM, Crawford FA. Right
ventricular outflow reconstruction with cryopreserved homografts in
pediatric patients: intermediate term follow-up with serial echocardio-
graphic assessment. J Am Coll Cardiol. 1994;24:483-9.
9. Bando K, Danielson GK, Schaff HV, Mair DD, Julsrud PR, Puga FJ.
Outcome of pulmonary and aortic homografts for right ventricular outflow
tract obstruction. J Thorac Cardiovasc Surg. 1995;109:509-18.
10. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD,
Fedderly RT, et al. Factors affecting longevity of homograft valves
used in right ventricular outflow tract reconstruction for congenital
heart disease. Circulation. 2000;102(suppl III):III130-5.
11. Schorn K, Yankah AC, Alexi-Meskhishvili V, Weng Y, Lange PE,
Hetzer R. Risk factors for early degeneration of allografts in pulmo-
nary circulation. Eur J Cardiothorac Surg. 1997;11:62-9.
12. Kay PH, Ross DN. Fifteen years experience with the aortic homograft:
the conduit of choice for right ventricular outflow reconstruction. Ann
Thorac Surg. 1985;40:360-5.
13. Bull C, Macartney FJ, Horvath P, Almeida R, Merrill W, Douglas J, et
Multivariate analysis
P value Hazard ratio (95% CI) P value
.019 4.07 (1.25-13.23) .020
.015 2.26 (1.17-4.34) .015
.018 — —
.002 — —isal. Evaluation of long term results of homograft and heterograft valves
in extracardiac conduits. J Thorac Cardiovasc Surg. 1987;94:12-9.
c and Cardiovascular Surgery ● Volume 130, Number 2 285
Surgery for Congenital Heart Disease Selamet Tierney et al
CH
D14. Cleveland DC, Williams WG, Razzouk AJ, Trusler GA, Rebeyka IM,
Duffy L, et al. Failure of cryopreserved homograft valved conduits in
the pulmonary circulation. Semin Thorac Cardiovasc Surg. 1992;
86(suppl II):II150-3.
15. Daenen W, Narine K, Goffin Y, Gewillig M. Right ventricular outflow
reconstruction with homografts. Eur J Cardiothorac Surg. 1995;9:
448-52.
16. Danielson GK, Anderson BJ, Schleck CD, Ilstrup DM. Late results of
pulmonary ventricle to pulmonary artery conduits. Semin Thorac Car-
diovasc Surg. 1995;7:162-7.
17. Hawkins JA, Bailey WB, Dillon T, Schwartz DC. Midterm results with
cryopreserved allograft valved conduits from the right ventricle to the
pulmonary arteries. J Thorac Cardiovasc Surg. 1992;104:910-6.
18. Homann M, Haehnel JC, Mendler N, Paek SU, Holper K, Meisner H,
et al. Reconstruction of the RVOT with valved biological conduits: 25
years experience with allografts and xenografts. Eur J Cardiothorac
Surg. 2000;17:624-30.286 The Journal of Thoracic and Cardiovascular Surgery ● Augusubpulmonary homograft conduits: determinants of late homograft
failure. J Thorac Cardiovasc Surg. 1998;115:506-16.
20. Sinzobahamvya N, Wetter J, Blaschczok HC, Cho M, Brecher AM,
Urban AE. The fate of small-diameter homografts in the pulmonary
position. Ann Thorac Surg. 2001;72:2070-6.
21. Perron J, Moran AM, Gauvreau K, del Nido PJ, Mayer JE, Jonas RA.
Valved homograft conduit repair of the right heart in early infancy.
Ann Thorac Surg. 1999;68:542-8.
22. Albert JD, Bishop DA, Fullerton DA, Campbell DN, Clarke DR.
Conduit reconstruction of the right ventricular outflow tract. J Thorac
Cardiovasc Surg. 1993;106:228-36.
23. Baskett RJ, Ross DB, Nanton MA, Murphy DA. Factors in early failure
of cryopreserved homografts pulmonary valves in children: preserved
immunogenicity? J Thorac Cardiovasc Surg. 1996;112:1170-8.
24. Carr-White GS, Kilner PJ, Hon JKF, Rutledge T, Edwards S, Burman
ED, et al. Incidence, location, pathology, and significance of pulmo-
nary homograft stenosis after the Ross operation circulation. Circula-19. Stark J, Bull C, Stajevic M, Jothi M, Elliott M, de Leval M. Fate of tion. 2001;104(suppl I):I16-20.st 2005
